Hims & Hers Health Inc SEC Filings

Hims & Hers Health director Deborah M. Autor was granted 3,656 Restricted Stock Units (RSUs) that convert one-for-one into Class A common shares. The award was recorded as an acquisition of derivative securities and increases her direct beneficial ownership to 3,656 shares at a reported price of $0. The RSUs are subject to a service-based vesting schedule and will vest on the earlier of the company’s 2026 annual meeting or June 15, 2026, provided continuous service.

This filing reflects an equity grant to a board director rather than a cash transaction or sale, creating potential alignment between the director and shareholders through future ownership if vesting conditions are met.

Carroll Patrick Harrison, Chief Medical Officer and a director of Hims & Hers Health, Inc. (HIMS), reported the sale of 60,000 shares of Class A common stock on 08/06/2025 at a weighted average price of $53.5813 per share (sales ranged from $53.19 to $53.97). After the sale his direct beneficial ownership of Class A shares is reported as 169,940 shares.

The filing also discloses a grant of 3,656 Restricted Stock Units (RSUs) that each convert into one share of Class A common stock subject to continuous service; the RSUs vest on the earlier of the 2026 annual meeting of stockholders or June 15, 2026. The filer represents the sale price as an average weighted price and offers to provide further allocation details upon request.

Hims & Hers director Manuel Anja was granted 3,656 Restricted Stock Units (RSUs) on 08/06/2025, each representing a contingent right to one share of Class A common stock. The filing reports 3,656 shares beneficially owned following the grant and lists the ownership form as Direct (D). Vesting requires continuous service and occurs at the earlier of the company27s 2026 annual meeting or June 15, 2026, meaning the award will convert to shares only if service continues until that event. The grant specifies a $0 price for the RSUs and does not include performance-based conditions in the explanation provided.

Hims & Hers Health, Inc. disclosed that director Schultz Kare was granted 3,656 restricted stock units (RSUs), each representing a contingent right to receive one share of Class A common stock. The RSUs vest subject to continuous service on the earlier of the company’s 2026 annual meeting or June 15, 2026, and will convert into 3,656 Class A shares upon vesting. The report shows the award is held in direct form and reflects equity-based, time‑based compensation for a board member rather than a cash transaction or sale. Without information on total outstanding shares, the absolute size of this grant limits assessment of materiality, but the filing documents a routine director equity award and alignment of the director’s interests with long‑term shareholder value.

Pendarvis Christiane, a director of Hims & Hers Health, Inc. (HIMS), was granted 3,656 Restricted Stock Units (RSUs) on 08/06/2025. Each RSU represents a contingent right to receive one share of Class A common stock at no cash price, and the award is recorded as a direct ownership interest of 3,656 shares following the grant.

The RSUs vest subject to continuous service on the earlier of the company’s 2026 annual meeting of stockholders or June 15, 2026, meaning the award is intended to align the director’s incentives with shareholder outcomes over the coming year.

Hims & Hers Health, Inc. (HIMS) – Form 144 filing: An unnamed insider has notified the SEC of a proposed sale of 60,000 Class A shares, representing roughly 0.03 % of the 217.6 million shares outstanding. The shares have an aggregate market value of $3,214,880.58 and are expected to be sold on or about 08/06/2025 through the NYSE using Fidelity Brokerage Services.

The shares derive from two equity-compensation events:

• 39,721 shares acquired on 02/28/2022 via a stock-option exercise paid in cash.
• 20,279 shares vested on 06/15/2025 as restricted-stock compensation.

This filing signals an intended discretionary liquidation by a company affiliate; while small relative to total float, it may be interpreted by investors as a modest insider-sentiment data point.